Business Context and Reporting Period
This Form 8-K was filed by Angion Biomedica Corp. (not Elicio Therapeutics, Inc.) on March 30, 2022. The filing serves to announce financial results for the fiscal quarter and full year ended December 31, 2021. The company is an emerging growth company incorporated in Delaware, with its common stock (ANGN) trading on the Nasdaq Global Select Market.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are referenced as being contained within Exhibit 99.1 (the press release), which is incorporated by reference but not included in the text of this 8-K summary.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the text body. It directs readers to the press release (Exhibit 99.1) for the announcement of results for the quarter and full year ended December 31, 2021.
Guidance, Outlook, and Risks
The text of this 8-K does not provide specific guidance, outlook, management commentary, or risk factors. It states that the information furnished, including the press release, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated March 30, 2022), as they are not present in the 8-K text.
- Confirm the discrepancy between the requested company name ("Elicio Therapeutics, Inc.") and the actual registrant ("Angion Biomedica Corp.").
- Review the full press release for any forward-looking statements or guidance that may have been issued alongside the financial results.
- Check the company's status as an emerging growth company for potential differences in financial reporting standards.